Medication Management for Primary Aldosteronism Screening
According to the most recent 2025 AHA/ACC and 2025 Endocrine Society guidelines, you can proceed with screening for primary aldosteronism WITHOUT stopping ARBs, clonidine, amlodipine, or nebivolol, though the results must be interpreted in the context of these medications. 1, 2
Two Acceptable Approaches
The latest guidelines recognize two valid strategies:
Approach 1: Screen Without Medication Changes (Preferred for Most Patients)
Conduct aldosterone-to-renin ratio (ARR) testing while patients remain on their current medications, including ARBs, clonidine, amlodipine, and nebivolol. 1, 3
Advantages:
- Reduces barriers to screening
- Avoids potentially dangerous blood pressure destabilization
- Prevents delays in diagnosis
- Particularly important in patients with uncontrolled hypertension
Key caveat: Results require interpretation by a hypertension specialist or endocrinologist who understands how these medications affect the ARR 3
Approach 2: Selective Medication Adjustment (For "Clean" Screening)
If you want the most reliable interpretation, medications can be adjusted as follows:
Medications to STOP (if safe and feasible):
- ARBs: Withdraw for 2 weeks 2
- Nebivolol (beta-blocker): Withdraw for 2 weeks 4, 3, 2
- Clonidine (centrally acting agent): Withdraw for 2 weeks 4, 3
Medication to CONTINUE:
- Amlodipine (dihydropyridine CCB): Can continue, though some guidelines suggest it may minimally interfere 3
Substitute with non-interfering agents:
- Long-acting calcium channel blockers (verapamil, diltiazem)
- Alpha-receptor antagonists (doxazosin, prazosin, terazosin)
- Hydralazine 4, 1, 3
Critical Understanding of Drug Effects
Beta-blockers (nebivolol) and centrally acting agents (clonidine) suppress both renin and aldosterone, potentially causing false-positive ARR results 1, 3, 5
ARBs stimulate renin and suppress aldosterone, potentially causing false-negative ARR results 1, 2, 5
Dihydropyridine CCBs (amlodipine) have minimal to no interference with ARR according to most recent evidence, though older guidelines suggested potential effects 3
The 2025 Paradigm Shift
The 2025 guidelines represent a major departure from older recommendations that mandated strict medication withdrawal. The Endocrine Society now explicitly states that screening can proceed without withdrawing interfering medications, recognizing that the risks of medication changes (hypertensive crises, cardiovascular events) often outweigh the benefits of "cleaner" testing 2, 1
The 2024 ESC guidelines similarly emphasize that "not every patient receiving β-blockers, ACEIs, ARBs and DHP-CCBs with negative reports needed withdrawal or switching antihypertensive drugs" 6
Practical Algorithm
Initial screening: Perform ARR on current medications (including ARBs, clonidine, amlodipine, nebivolol)
If ARR is clearly positive (high aldosterone, suppressed renin): Proceed to confirmatory testing or specialist referral
If ARR is borderline or negative BUT clinical suspicion remains high (resistant hypertension, hypokalemia): Consider repeating after medication adjustment
If beta-blockers or clonidine are present and ARR is positive: Consider repeating after 2-week withdrawal to rule out false-positive, especially if aldosterone is 10-15 ng/dL 2
Essential Pre-Test Conditions (Regardless of Medication Approach)
- Correct hypokalemia (can cause false-negatives) 4, 1, 2
- Liberal sodium intake (>200 mmol/day or >5g/day) 4
- Morning collection after 2 hours upright 4
- Seated for 5-15 minutes before blood draw 4
Common Pitfall to Avoid
Do not automatically withdraw all medications before screening. This outdated practice has been a major barrier to PA diagnosis and can endanger patients with severe hypertension 1, 3. The 2025 guidelines explicitly address this as a reason for historically low screening rates.